About this Research Topic
Gynecologic cancers, including cervical, ovarian, endometrial, vaginal, and vulvar cancers, represent a significant health burden for women globally. Recent advancements in immunology have opened new avenues for understanding and treating these malignancies. Immunotherapy, particularly the use of immune checkpoint inhibitors, has shown promise in improving patient outcomes. Despite these advancements, there is still much to learn about the immunological landscape of gynecologic cancers and how these insights can be harnessed for more effective therapies.
The primary goal of this Research Topic is to explore the intricate immunological mechanisms underpinning gynecologic cancers and to investigate the potential of immunotherapy in treating these diseases. We aim to address the following key issues: What are the unique immunological features of gynecologic cancers? How can we leverage immune checkpoint inhibitors and other immunotherapies to improve treatment outcomes? What are the challenges and limitations in current immunotherapeutic approaches? Recent advances in immunotherapy, such as combination therapies and personalized medicine, will also be examined to provide a comprehensive overview of current and future strategies.
By compiling a diverse array of studies and perspectives, this Research Topic aims to enhance our understanding of the immunological underpinnings of gynecologic cancers and to highlight innovative approaches to treatment. We invite researchers and clinicians to contribute to this Research Topic by submitting original research articles, reviews, clinical trials, methods, hypotheses/theories, perspectives, opinions, and commentaries that address the following themes:
• Immunological characteristics of cervical, ovarian, endometrial, vaginal, and vulvar cancers
• Mechanisms of immune evasion and resistance in gynecologic cancers
• Development and application of immune checkpoint inhibitors
• Combination therapies involving immunotherapy and other treatment modalities
• Biomarkers for predicting response to immunotherapy
• Personalized immunotherapeutic approaches
• Case studies and clinical trials on immunotherapy in gynecologic cancers
Note that Professor Bastian Czogalla receives honoraria from AstraZeneca and Prof Anna Jaeger from MSD, GSK, Roche Diagnostics, Astra Zeneca, Molecular Health, Clovis Oncology, Gedeon Pharma. Please also note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.
The primary goal of this Research Topic is to explore the intricate immunological mechanisms underpinning gynecologic cancers and to investigate the potential of immunotherapy in treating these diseases. We aim to address the following key issues: What are the unique immunological features of gynecologic cancers? How can we leverage immune checkpoint inhibitors and other immunotherapies to improve treatment outcomes? What are the challenges and limitations in current immunotherapeutic approaches? Recent advances in immunotherapy, such as combination therapies and personalized medicine, will also be examined to provide a comprehensive overview of current and future strategies.
By compiling a diverse array of studies and perspectives, this Research Topic aims to enhance our understanding of the immunological underpinnings of gynecologic cancers and to highlight innovative approaches to treatment. We invite researchers and clinicians to contribute to this Research Topic by submitting original research articles, reviews, clinical trials, methods, hypotheses/theories, perspectives, opinions, and commentaries that address the following themes:
• Immunological characteristics of cervical, ovarian, endometrial, vaginal, and vulvar cancers
• Mechanisms of immune evasion and resistance in gynecologic cancers
• Development and application of immune checkpoint inhibitors
• Combination therapies involving immunotherapy and other treatment modalities
• Biomarkers for predicting response to immunotherapy
• Personalized immunotherapeutic approaches
• Case studies and clinical trials on immunotherapy in gynecologic cancers
Note that Professor Bastian Czogalla receives honoraria from AstraZeneca and Prof Anna Jaeger from MSD, GSK, Roche Diagnostics, Astra Zeneca, Molecular Health, Clovis Oncology, Gedeon Pharma. Please also note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.
Keywords: Gynecologic cancers, cervical cancer, ovarian cancer, endometrial cancer, vaginal cancer, vulvar cancer, immunotherapy, immune checkpoint inhibitors, immune evasion, biomarkers
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
